Anti-p-RPS6KB1 (Thr389) Antibody, clone 1K19 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1K19 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects p70 S6 Kinase (RPS6KB1) phosphorylated on threonine on 412 and, the human splice variant of p70 S6 kinase phosphorylated on threonine 389.

KLH-conjugated linear peptide corresponding to 13 amino acids from the C-terminal half of human p70 S6 Kinase (RPS6KB1).

Quality Control Testing

Evaluated by Western Blotting in NIH/3T3 cells treated with calyculin A/okadaic acid.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected p-RPS6KB1 (Thr389) in NIH/3T3 cells treated with calyculin/okadaic acid (serum starved overnight, 50 nM calyculin A, 500 nM okadaic acid for 30min).

Tested Applications

Enzyme Immunoassay: A representative lot of this antibody detected p-RPS6KB1(Thr389) in ELISA application.

Peptide Inhibition Assay: Target band detection in lysate from NIH/3T3 cells treated with calyculin/okadaic acid (serum starved overnight, 50 nM calyculin A, 500 nM okadaic acid, 30 min) was prevented by pre-blocking of a representative lot with the RPS6KB1 phosphorylated peptide, but not the corresponding non-phosphorylated peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Ribosomal protein S6 kinase beta-1 (UniProt: P23443; also known as EC:2.7.11.1, S6K-beta-1; S6K1, 70 kDa ribosomal protein S6 kinase 1 (P70S6K1; p70-S6K 1), Ribosomal protein S6 kinase I, Serine/threonine-protein kinase 14A, p70 ribosomal S6 kinase alpha (p70 S6 kinase alpha; p70 S6K-alpha; p70 S6KA)) is encoded by the RPS6KB1 (also known as STK14A) gene (Gene ID: 6198) in human. The p70 S6 kinase is a ubiquitous cytoplasmic protein that is activated in response to cytokines, and growth factors including the epidermal growth factor and fibroblast growth factor. It lies downstream of the mTOR/PI3K pathway and is phosphorylated on multiple residues: Thr389, Thr229, Thr421, Ser371, Ser404, Ser411, Ser418, and Ser424. Thr389, Ser371, and Ser404 are located in the linker domain; whereas Thr421, Ser411, Ser418, Ser424 are located in the autoinhibitory domain, and Thr229 is found in the catalytic domain. These sites may be phosphorylated in a hierarchical sequence leading to the activation of the p70 S6 kinase. The phosphorylation at threonine 389 (Thr389) is a key regulatory modification that activates the kinase. This activation is primarily mediated by the mTOR (mechanistic target of rapamycin) signaling pathway, which responds to various cellular stimuli such as nutrients, growth factors, and energy status. Upon activation, p70 S6 Kinase enhances the translation of specific mRNAs, particularly those involved in ribosomal biogenesis and protein synthesis, thus promoting cell growth and proliferation. Dysregulation of p70 S6 Kinase activity, including aberrant phosphorylation at Thr389, has been implicated in various pathological conditions, including cancer, metabolic disorders, and neurological diseases. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.